Business Context and Reporting Period
Company: Curis, Inc. (CRIS)
Filing Type: Form 8-K (Current Report)
Date of Report: February 3, 2026
Reporting Period: Event date February 3, 2026; Signed February 9, 2026
Business Context: The Company is a biopharmaceutical entity listed on the Nasdaq Capital Market. This filing addresses the status of its listing compliance following a prior deficiency.
Key Financial Metrics
This Form 8-K is a current report regarding corporate governance and listing status. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
- Regaining Compliance: On February 3, 2026, Curis, Inc. received written notice from Nasdaq confirming it has regained compliance with Nasdaq Listing Rule 5550(b)(2) (Minimum Value of Listed Securities Rule).
- Panel Decision: The Company is now in full compliance with the terms set forth by the Nasdaq Hearings Panel.
Outlook, Risks, and Contingencies
- Monitoring Period: The Company is subject to a Discretionary Panel Monitor for a period of one year.
- Future Non-Compliance Risk: If the Company falls out of compliance with any Nasdaq Listing Rule within the one-year monitoring period, it will not be permitted to submit a plan of compliance or receive additional cure time. Instead, Nasdaq Staff will issue a Delist Determination Letter immediately.
- Delisting Consequence: Following a Delist Determination Letter during the monitoring period, the Company may be delisted from Nasdaq, though it retains the right to request a hearing.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results regarding listing maintenance may differ from expectations.
Investor Verification Checklist
- Verify the specific metrics used to regain compliance with Nasdaq Listing Rule 5550(b)(2) (e.g., share price or market value of listed securities) in recent trading data.
- Monitor the Company's stock price and market capitalization closely over the next 12 months to ensure continued compliance.
- Review the Company's most recent Form 10-K (for the year ended December 31, 2024) for detailed risk factors and financial health context not included in this 8-K.
- Confirm the exact start date of the one-year monitoring period to track the deadline for potential delisting risks.